WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 1001
[post_author] => 1
[post_date] => 2014-06-04 05:56:55
[post_date_gmt] => 2014-06-04 05:56:55
[post_content] => CFB Client Company, Intensity Therapeutics, Inc. established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity?s in situ chemovaccination products using in vivo models of cancer. Read the full press release here.
[post_title] => Intensity Therapeutics Awarded CRADA from National Cancer Institute
[post_excerpt] => A CFB Client Company established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => intensity-therapeutics-awarded-crada-from-national-cancer-institute
[to_ping] =>
[pinged] =>
[post_modified] => 2015-01-28 17:06:52
[post_modified_gmt] => 2015-01-28 17:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1001
[menu_order] => 229
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3794
[post_author] => 3
[post_date] => 2021-06-15 14:59:52
[post_date_gmt] => 2021-06-15 14:59:52
[post_content] =>
Join our team! The Center for Biotechnology is recruiting an Assistant Director for Technology and Business Development. The Asst. Director for Technology and Business Development will develop and help implement milestone driven commercialization strategies, and provide oversight to Commercialization Associates who have primary responsibility for conducting due diligence to guide and support Center for Biotechnology/LIBH “investments".
The incumbent will serve as the primary contact with
internal and external parties on issues related to research, technology
development and commercialization, and foster new collaborative relationships
leading to sponsored research agreements and possible strategic alliances with
external partners including bioscience companies and investors.
Read the full position description and apply via the “stony Brook at work” website: https://stonybrooku.taleo.net/careersection/jobdetail.ftl?job=2101841&lang=en
Questions? Contact Anne DePietri (annette.depietri@stonybrook.edu) at the Center for Biotechnology.
[post_title] => CFB Career Opportunity: Assistant Director for Technology and Business Development
[post_excerpt] => The CFB is recruiting an Assistant Director for Technology and Business Development.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-career-opportunity-assistant-director-for-technology-and-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-22 13:09:32
[post_modified_gmt] => 2022-08-22 13:09:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3794
[menu_order] => 42
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2836
[post_author] => 1
[post_date] => 2017-09-29 14:45:07
[post_date_gmt] => 2017-09-29 14:45:07
[post_content] => Traverse Biosciences, lead by CFB BioEntrepreneur-in-Residence (B-EIR) Joseph Scaduto, has announced that the National Institutes of Health (NIH) has accepted the company into its competitive Commercialization Accelerator Program (CAP).
Hosted in partnership with the Larta Institute, NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in measurable gains and accomplishments by participating companies. It is open only to NIH SBIR/STTR Phase II awardees, with only 80 slots available each year. The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.
Last year, Traverse Biosciences announced that it had received a $1.3M Phase II Small Business Technology Transfer (STTR) award in partnership with the School of Dental Medicine at Stony Brook University. Read the full Traverse Biosciences announcement here.
[post_title] => Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP)
[post_excerpt] => CFB BEIR-led Traverse Biosciences will enter the exclusive 9-month program which enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => traverse-biosciences-accepted-into-nih-commercialization-accelerator-program-cap
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:39:02
[post_modified_gmt] => 2018-01-23 14:39:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2836
[menu_order] => 137
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 260
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
